Evidence map›Paper›PMID 31322911›Full record

ReviewThe British journal of radiology2019

Update in pediatric nasopharyngeal undifferentiated carcinoma.

Line Claude, Emmanuel Jouglar, Loig Duverge, Daniel Orbach

Open access · greenAbstract readReview
In one paragraph

Review in The British journal of radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. [Nasopharyngeal carcinoma in children: clinical analysis of 6 cases and literature review].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Advances in nasopharyngeal carcinomaThe British journal of radiology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Line ClaudeDepartment of radiotherapy, Centre Léon Bérard, Lyon, France.
Emmanuel JouglarDepartment of radiotherapy, Institut de Cancérologie de l'Ouest - Centre René Gauducheau, Saint-Herblain, France.
Loig DuvergeDepartment of radiotherapy, Centre Léon Bérard, Lyon, France.
Daniel OrbachSIREDO oncology center (Care, Innovation and Research for Children, Adolescents and Young Adults with cancer), Institut Curie, PSL university, Paris, France.
Centre Léon Bérard · FRInstitut Curie · FRInstitut de Cancérologie de l'Ouest · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many of the principles established in adults with undifferentiated nasopharyngeal carcinoma (NPC) apply to children, adolescents and young adults. However, NPC in young patients should be distinguished from the adult form by several points. This review focuses mainly on differences between adult and pediatric NPC. The role of biology and genetics in pediatric NPC is discussed. Systemic treatment modalities including type of chemotherapy induction, timing of treatment, role of immunotherapy as adjuvant treatment, or in relapsing/ metastatic diseases are reported. Radiation modalities (doses, techniques…) in children are also reviewed. Long-term effects including secondary cancers are finally be discussed in this young NPC population.

Indexed as

AdolescentAge FactorsAntineoplastic AgentsChemotherapy, AdjuvantChildHerpesvirus 4, HumanHumansInduction ChemotherapyInterferon-betaMaintenance ChemotherapyNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNeoplasm StagingRadiotherapyYoung AdultAntineoplastic AgentsInterferon-beta

Identifiers

PMID31322911
PMCPMC6774591
OpenAlexW2962977377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.